Why Novavax (NVAX) Stock Is Rising

Novavax Inc NVAX shares are trading higher by some 3.9% to $8.36 Monday morning. The stock is gaining amid rising COVID-19 cases in the U.S.

Given the rise in cases and concerns about variants, health authorities may emphasize the need for booster shots. A Novavax vaccine could be a candidate for booster campaigns, leading to increased market demand and a potential rise in the stock price.

In general, higher vaccine sales due to increased COVID-19 cases could significantly improve Novavax's financial outlook. Stronger revenue from vaccine orders and government contracts could attract investor attention and potentially drive the stock price higher.

What Else?

Last week, during the first Republican primary debate, Florida Gov. Ron DeSantis proudly touted the way he handled the Covid-19 pandemic, claiming the Sunshine State "led the country out of lockdown, and we kept our state free and open."

Meanwhile, COVID-19 hospitalizations in Florida saw more than 1,870 new admissions in the week ending Aug. 12 — an increase of 11.6% from the prior week.

The situation reflects a larger trend across the country: More than 12,600 new admissions were recorded the week ending Aug. 12. That's an increase of 21.6% from the prior week, according to data from the U.S. Centers for Disease Control and Prevention...Read More

According to data from Benzinga Pro, Novavax has a 52-week high of $37.27 and a 52-week low of $5.60.